Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc Common Stock
Your view on CURX
Overview
What the company does, where it operates, and who runs it.
About Curanex Pharmaceuticals Inc Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jun Liu
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jun Liu
- Headquarters
- US
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases.
It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023.
The company was founded in 1996 and is headquartered in Jericho, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Curanex Pharmaceuticals Inc Common Stock, and the rating behind it. CURX last traded at $4.55; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Curanex Pharmaceuticals Inc Common Stock. Starting points for Curanex Pharmaceuticals Inc Common Stock: EPS -$7.38, beta -2.57 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Curanex Pharmaceuticals Inc Common Stock. Curanex Pharmaceuticals Inc Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Curanex Pharmaceuticals Inc Common Stock. Trailing twelve-month EPS for Curanex Pharmaceuticals Inc Common Stock stands at -$7.38. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Curanex Pharmaceuticals Inc Common Stock. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Curanex Pharmaceuticals Inc Common Stock valued side by side against its closest peers. Curanex Pharmaceuticals Inc Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Curanex Pharmaceuticals Inc Common Stock, and how their positions are changing. At a $6.4M market value, institutional positions materially move Curanex Pharmaceuticals Inc Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Curanex Pharmaceuticals Inc Common Stock executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Curanex Pharmaceuticals Inc Common Stock. Curanex Pharmaceuticals Inc Common Stock is a $6.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Curanex Pharmaceuticals Inc Common Stock. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Curanex Pharmaceuticals Inc Common Stock. Coverage tracks Curanex Pharmaceuticals Inc Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.